Rupal Desai

Molecular Classification of Human Cancers Using a 92‐Gene Real-Time Quantitative Polymerase Chain Reaction Assay

Xiaojun Ma, R. D. Patel, Xianqun Wang et al. · Archives of Pathology & Laboratory Medicine · 2006 · 198 citations

Medicine, Molecular Biology, Oncology +17

Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay.

Xiaojun Ma, R. D. Patel, Xianqun Wang et al. · PubMed · 2006 · 193 citations

Medicine, Molecular Biology, Oncology +17

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

David Isenberg, Richard Furie, Nicholas S. Jones et al. · Arthritis & Rheumatology · 2021 · 134 citations

Medicine, Pharmacology, Pharmacotherapy +16

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha et al. · Clinical Cancer Research · 2014 · 133 citations · Full text

Medicine, Oncology, Pharmacology +17

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen et al. · Clinical Cancer Research · 2022 · 90 citations · Full text

Medicine, Oncology, Pharmacology +14